All posts by: Michael Zand

T-Cell Therapy JCAR017 Eliminates Tumor Cells in Half of DLBCL Patients in Phase 1 Trial – Lymphoma News Today

Lymphoma News TodayT-Cell Therapy JCAR017 Eliminates Tumor Cells in Half of DLBCL Patients in Phase 1 TrialLymphoma News TodayJCAR017 is a chimeric antigen receptor (CAR) T-cell product that specifically targets CD19, a protein expressed on the surface… Continue reading

Synthetic biology and the fountain of youth – The Straits Times

Synthetic biology and the fountain of youthThe Straits TimesSynthetic biology is the design and building of biological systems to improve existing functions or introduce new purposes. It draws inspiration from nature and uses materials offered by the l… Continue reading

News from the AAN Annual Meeting: Gene Therapy Found to Benefit Infants with SMA Type 1 in Open-Label Trial – LWW Journals

News from the AAN Annual Meeting: Gene Therapy Found to Benefit Infants with SMA Type 1 in Open-Label TrialLWW JournalsIn a new gene therapy trial, infants with spinal muscular atrophy survived longer without adverse events and achieved developmental m… Continue reading

Cancer Immunotherapy Market Research Report and Forecast up to 2024 – Medgadget (blog)

Cancer Immunotherapy Market Research Report and Forecast up to 2024Medgadget (blog)The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasin… Continue reading

Cancer Immunotherapy Market Research Report and Forecast up to 2024 – Medgadget (blog)

Cancer Immunotherapy Market Research Report and Forecast up to 2024Medgadget (blog)The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasin… Continue reading

There’s a race to get 2 revolutionary new cancer treatments on the market — here’s who’s in the lead – Business Insider

Business Insider

There’s a race to get 2 revolutionary new cancer treatments on the market — here’s who’s in the lead Business Insider Two cutting-edge treatments for blood cancers are poised to get approved by the end of the year. The highly personalized treatment is called CAR T-cell therapy. It’s a type of cancer immunotherapy, or a therapy that harness the body’s immune system to … How will Novartis price its groundbreaking CAR–T med? R&D exec offers some cluesFiercePharma Novartis’ CAR–T shows durable response in lymphoma patientsPharmaTimes Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment …Bloomberg all 13 news articles »

Business Insider

There’s a race to get 2 revolutionary new cancer treatments on the market — here’s who’s in the lead Business Insider Short for chimeric antigen receptor T–cell therapy, CAR-T treatment takes a person’s own cells, removes them from the body, re-engineers them, and then puts the cells back in the body where they can attack cancer cells. There are a handful of companies … Novartis’ CAR–T shows durable response in lymphoma patientsPharmaTimes Small Biotech Pops As Rival Novartis Struggles To Keep PaceInvestor’s Business Daily Novartis’s Next Challenge: Pricing Breakthrough Cancer TreatmentBloomberg Market Exclusive –Smаrt Stоck Nеws all 13 news articles »

Healio

VIDEO: Precision medicine, immunotherapy show promise in neuro-oncology research Healio CHICAGO — Andrew B. Lassman, MD, discusses advances made within two major themes — precision medicine and immunotherapy — for the treatment of primary brain tumors at the ASCO Annual Meeting. Lassman, chief of neuro-oncology at Columbia …